Instead, to really establish that CD36+CD8+ T cells impacted the immune response to chemotherapy specifically, the inferior response should be shown in patients with stage II-III NSCLC who had surgery and chemotherapy, and not shown in patients who had surgery alone. The gene discussed is CD36; the disease is non-small cell lung carcinoma.